ClinicalTrials.gg
CompletedNCT01631825Updated Mar 19, 2014Results posted

A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

A Phase 3 interventional study of SPM 962 in Parkinson's Disease, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Per ClinicalTrials.gov, last updated 2014-03-19.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
321
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
9th of 42
321 · median 123
Started
2009
with 1 other
Phase 3
20 of 44
none open now
Registered
25th of 44
by date
Lead sponsor
7 of 44
Otsuka Pharmaceutical Co., Ltd.

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 9th largest by enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2009, is one of 20 in phase 3, and was the 25th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

  • To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in a multi-center, open-label uncontrolled study.
  • To investigate efficacy of SPM 962 in an exploratory manner.
03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • SPM 962
  • rotigotine
  • Parkinson's disease
  • concomitant use of L-dopa
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject completed the preceding trial 243-08-001.

Exclusion criteria

Exclusion Criteria:

  • Subject discontinued from the preceding trial 243-08-001.
  • Subject had a serious adverse event which association with the drug was not ruled out during trial 243-08-001.
  • Subject has a persistent serious adverse event at the baseline, which was observed and association with the investigational drug was ruled out during trial 243-08-001.
  • Subject had persistent confusion, hallucination, delusion or excitation during trial 243-08-001.
  • Subject has abnormal behavior such as obsessive-compulsive disorder and delusion in 243-08-001 study.
  • Subject showed serious or extensive application site reactions beyond the application site in the 243-08-001 study.
  • Subject has orthostatic hypotension or a systolic blood pressure (SBP) \<= 100 mmHg and has a decrease of SBP from spine to standing position >= 30 mmHg at baseline.
  • Subject has a history of epilepsy, convulsion etc. during trial 243-08-001.
  • Subject develops serious abnormality at the baseline.
  • Subject has -interval >= 500 msec at the baseline or subject has an increase of QTc-interval >= 60 msec from the baseline in the trial 243-08-001 and has a QTc-interval > 470 msec in female or > 450 msec in male at the baseline.
  • Subject had a serum potassium level \< 3.5 mEq/L at the end of the taper period in trial 243-08-001.
  • Subject has a total >= 3.0 mg/dL or (GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or ? 100 IU/L) at the end of the period in trial 243-08-001.
  • Subject had BUN >= 30 mg/dL or serum creatinine >= 2.0 mg/dl at the end of the taper period in trial 243-08-001.
  • Subject who plans pregnancy during the trial.
  • Subject is unable to give consent.
  • Subject is judged to be inappropriate for this trial by the investigator for the reasons other than above.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
321 participants (actual)

Study arms

  • Experimental
    SPM 962

    SPM 962 transdermal patch

    Drug: SPM 962

Interventions

  • SPM 962 transdermal patch once a daily up to 36.0 mg/day

    Also known as: rotigotine

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters

    The safety of the long-term SPM 962 treatment was examined based on the incidence and severity of AEs, vital signs, and laboratory parameters. AEs of special interest (1-3) are defined as below: 1. sudden onset of sleep 2. obsessive-compulsive disorder or impulse-control disorder 3. hallucination, delusion Application site reaction is scored as -, ±, +, ++, +++, or ++++. More + indicates a greater severity of symptoms. The worst score obtained throughout the evaluation period was to be assessed.

    Time frame: Up to 55 weeks after dosing

Secondary outcomes

  1. Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score

    Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state). UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, Up to 54 weeks after dosing

  2. UPDRS Part 2 Sum Score (Average of on State and Off State)

    Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average of on state and off state). UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, up to 54 weeks after dosing

  3. Absolute Time Spent "Off"

    Mean number of hours in "off state" during a 24-hour period.

    Time frame: Baseline, up to 54 weeks after dosing

  4. UPDRS Part 1 Sum Score

    Mean change (LOCF) from baseline in UPDRS Part 1 sum score. UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, up to 54 weeks after dosing

  5. UPDRS Part 2 Sum Score (On State)

    Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state). A decrease in the scores means improvement.

    Time frame: Baseline, up to 54 weeks after dosing

  6. UPDRS Part 2 Sum Score (Off State)

    Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state). A decrease in the scores means improvement.

    Time frame: Baseline, up to 54 weeks after dosing

  7. UPDRS Part 4 Sum Score

    Mean change (LOCF) from baseline in UPDRS Part 4 sum score. UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, up to 54 weeks after dosing

  8. Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average of on State and Off State), UPDRS Part 3 Sum Score (on State), and UPDRS Part 4 Sum Score

    Mean change (LOCF) from baseline in total of UPDRS Part 1 sum score, UPDRS Part 2 sum score (average of on state and off state), UPDRS Part 3 sum score (on state), and UPDRS Part 4 sum score. A decrease in the scores means improvement.

    Time frame: Baseline, up to 54 weeks after dosing

  9. The Modified Hoehn & Yahr Severity of Illness

    Change (LOCF) from baseline in the Modified Hoehn \& Yahr Severity of Illness. The Modified Hoehn \& Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided. The data at week 52 is shown.

    Time frame: Baseline, up to 54 weeks after dosing.

  10. Each Item of UPDRS Part 1

    The percentage of subjects with elevated scores for each item of UPDRS Part 1. The data at week 52 is shown.

    Time frame: Baseline, up to 54 weeks after dosing.

  11. Each Item of UPDRS Part 2 (on State)

    The percentage of subjects with elevated scores for each item of UPDRS Part 2 (on state). The data at week 52 is shown.

    Time frame: Baseline, up to 54 weeks after dosing.

  12. Each Item of UPDRS Part 2 (Off State)

    The percentage of subjects with elevated scores for each item of UPDRS Part 2 (off state). The data at week 52 is shown.

    Time frame: Baseline, up to 54 weeks after dosing.

  13. Each Item of UPDRS Part 2 (Average of on State and Off State)

    The percentage of subjects with elevated scores for each item of UPDRS Part 2 (average of on state and off state). The data at week 52 is shown.

    Time frame: Baseline, up to 54 weeks after dosing.

  14. Total of UPDRS Part 2 Sum Score (Average of on State and Off State) and UPDRS Part 3 Sum Score (on State)

    Mean change (LOCF) from baseline in total of UPDRS Part 2 sum score (average of on state and off state) and UPDRS Part 3 sum score (on state). A decrease in the scores means improvement.

    Time frame: Baseline, up to 54 weeks after dosing

  15. Each Item of UPDRS Part 3 (on State)

    The percentage of subjects with elevated scores for each item of UPDRS Part 3 (on state). The data at week 52 is shown.

    Time frame: Baseline, up to 54 weeks after dosing.

  16. Each Item of UPDRS Part 4

    The percentage of subjects with elevated scores for each item of UPDRS Part 4. The data at week 52 is shown.

    Time frame: Baseline, up to 54 weeks after dosing.

07

Results

Posted Mar 19, 2014

Participant flow

Participant flow — Overall Study
MilestoneSPM 962
Started321
Completed256
Not completed65
Withdrew: Adverse event42
Withdrew: Lack of efficacy7
Withdrew: Withdrawal by subject9
Withdrew: Protocol violation4
Withdrew: Discontinuation criteria1
Withdrew: Physician decision2

Outcome measures

PrimaryIncidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters

The safety of the long-term SPM 962 treatment was examined based on the incidence and severity of AEs, vital signs, and laboratory parameters. AEs of special interest (1-3) are defined as below: 1. sudden onset of sleep 2. obsessive-compulsive disorder or impulse-control disorder 3. hallucination, delusion Application site reaction is scored as -, ±, +, ++, +++, or ++++. More + indicates a greater severity of symptoms. The worst score obtained throughout the evaluation period was to be assessed.

Time frame:
Up to 55 weeks after dosing
Reported as:
Number · participants
Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters
participantsSPM 962
Any AEs311
Treatment-related AEs269
SAEs34
Treatment-related SAEs6
Severe AEs16
Discontinuation due to AEs47
Death1
AEs of special interest 17
AEs of special interest 24
AEs of special interest 354
Valvular disease of the heart0
Sitting systolic blood pressure, ≤ 100 mmHg9
QTcB ≥ 500 ms5
QTcF ≥ 500 ms2
Application site reaction ≥ +++14
Weight decrease reported as AE8
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score

Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state). UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, Up to 54 weeks after dosing
Reported as:
Mean · Scores on a scale
Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score
Scores on a scaleSPM 962
Week 12-8.3 ± 7.1
Week 24-8.0 ± 7.6
Week 52-7.5 ± 8.6
SecondaryUPDRS Part 2 Sum Score (Average of on State and Off State)

Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average of on state and off state). UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, up to 54 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 2 Sum Score (Average of on State and Off State)
Scores on a scaleSPM 962
Week 12-2.6 ± 3.0
Week 24-2.5 ± 3.4
Week 52-1.9 ± 4.0
SecondaryAbsolute Time Spent "Off"

Mean number of hours in "off state" during a 24-hour period.

Time frame:
Baseline, up to 54 weeks after dosing
Reported as:
Mean · Hours
Absolute Time Spent "Off"
HoursSPM 962
Week 12-2.5 ± 2.5
Week 24-2.5 ± 2.7
Week 52-2.0 ± 2.7
SecondaryUPDRS Part 1 Sum Score

Mean change (LOCF) from baseline in UPDRS Part 1 sum score. UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, up to 54 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 1 Sum Score
Scores on a scaleSPM 962
Week 12-0.33 ± 1.07
Week 24-0.25 ± 1.17
Week 52-0.15 ± 1.29
SecondaryUPDRS Part 2 Sum Score (On State)

Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state). A decrease in the scores means improvement.

Time frame:
Baseline, up to 54 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 2 Sum Score (On State)
Scores on a scaleSPM 962
Week 12-1.9 ± 2.8
Week 24-1.7 ± 3.0
Week 52-1.3 ± 3.7
SecondaryUPDRS Part 2 Sum Score (Off State)

Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state). A decrease in the scores means improvement.

Time frame:
Baseline, up to 54 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 2 Sum Score (Off State)
Scores on a scaleSPM 962
Week 12-3.7 ± 4.3
Week 24-3.8 ± 4.8
Week 52-2.5 ± 5.5
SecondaryUPDRS Part 4 Sum Score

Mean change (LOCF) from baseline in UPDRS Part 4 sum score. UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, up to 54 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 4 Sum Score
Scores on a scaleSPM 962
Week 12-0.24 ± 1.29
Week 24-0.28 ± 1.32
Week 52-0.13 ± 1.42
SecondaryTotal of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average of on State and Off State), UPDRS Part 3 Sum Score (on State), and UPDRS Part 4 Sum Score

Mean change (LOCF) from baseline in total of UPDRS Part 1 sum score, UPDRS Part 2 sum score (average of on state and off state), UPDRS Part 3 sum score (on state), and UPDRS Part 4 sum score. A decrease in the scores means improvement.

Time frame:
Baseline, up to 54 weeks after dosing
Reported as:
Mean · Scores on a scale
Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average of on State and Off State), UPDRS Part 3 Sum Score (on State), and UPDRS Part 4 Sum Score
Scores on a scaleSPM 962
Week 12-11.4 ± 9.7
Week 24-11.1 ± 10.5
Week 52-9.7 ± 12.1
SecondaryThe Modified Hoehn & Yahr Severity of Illness

Change (LOCF) from baseline in the Modified Hoehn \& Yahr Severity of Illness. The Modified Hoehn \& Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided. The data at week 52 is shown.

Time frame:
Baseline, up to 54 weeks after dosing.
Reported as:
Number · Percentage of participants
The Modified Hoehn & Yahr Severity of Illness
Percentage of participantsSPM 962
Increased7.3
Not changed62.5
Decreased30.2
SecondaryEach Item of UPDRS Part 1

The percentage of subjects with elevated scores for each item of UPDRS Part 1. The data at week 52 is shown.

Time frame:
Baseline, up to 54 weeks after dosing.
Reported as:
Number · Percentage of Participants
Each Item of UPDRS Part 1
Percentage of ParticipantsSPM 962
Intellectual impairment2.8
Thought disorder9.5
Depression5.0
Motivation/Initiative4.4
SecondaryEach Item of UPDRS Part 2 (on State)

The percentage of subjects with elevated scores for each item of UPDRS Part 2 (on state). The data at week 52 is shown.

Time frame:
Baseline, up to 54 weeks after dosing.
Reported as:
Number · Percentage of Participants
Each Item of UPDRS Part 2 (on State)
Percentage of ParticipantsSPM 962
Speech4.7
Salivation11.0
Swallowing6.0
Handwriting7.6
Cutting Food and Handling Utensils6.9
Dressing6.6
Hygiene5.0
Turning in Bed / Adjusting Bed Clothes7.9
Falling - Unrelated to Freezing8.2
Freezing When Walking6.6
Walking8.5
Tremor4.4
Sensory Complaints Related to Parkinsonism3.5
SecondaryEach Item of UPDRS Part 2 (Off State)

The percentage of subjects with elevated scores for each item of UPDRS Part 2 (off state). The data at week 52 is shown.

Time frame:
Baseline, up to 54 weeks after dosing.
Reported as:
Number · Percentage of Participants
Each Item of UPDRS Part 2 (Off State)
Percentage of ParticipantsSPM 962
Speech5.8
Salivation10.5
Swallowing6.3
Handwriting11.6
Cutting Food and Handling Utensils11.6
Dressing9.5
Hygiene11.6
Turning in Bed / Adjusting Bed Clothes10.5
Falling - Unrelated to Freezing9.5
Freezing When Walking17.9
Walking13.2
Tremor4.2
Sensory Complaints Related to Parkinsonism5.8
SecondaryEach Item of UPDRS Part 2 (Average of on State and Off State)

The percentage of subjects with elevated scores for each item of UPDRS Part 2 (average of on state and off state). The data at week 52 is shown.

Time frame:
Baseline, up to 54 weeks after dosing.
Reported as:
Number · Percentage of Participants
Each Item of UPDRS Part 2 (Average of on State and Off State)
Percentage of ParticipantsSPM 962
Speech6.7
Salivation13.7
Swallowing7.6
Handwriting12.1
Cutting Food and Handling Utensils11.1
Dressing9.2
Hygiene10.2
Turning in Bed / Adjusting Bed Clothes10.5
Falling - Unrelated to Freezing9.9
Freezing When Walking14.6
Walking12.7
Tremor5.7
Sensory Complaints Related to Parkinsonism5.7
SecondaryTotal of UPDRS Part 2 Sum Score (Average of on State and Off State) and UPDRS Part 3 Sum Score (on State)

Mean change (LOCF) from baseline in total of UPDRS Part 2 sum score (average of on state and off state) and UPDRS Part 3 sum score (on state). A decrease in the scores means improvement.

Time frame:
Baseline, up to 54 weeks after dosing
Reported as:
Mean · Scores on a scale
Total of UPDRS Part 2 Sum Score (Average of on State and Off State) and UPDRS Part 3 Sum Score (on State)
Scores on a scaleSPM 962
Week 12-10.9 ± 9.2
Week 24-10.5 ± 9.9
Week 52-9.4 ± 11.4
SecondaryEach Item of UPDRS Part 3 (on State)

The percentage of subjects with elevated scores for each item of UPDRS Part 3 (on state). The data at week 52 is shown.

Time frame:
Baseline, up to 54 weeks after dosing.
Reported as:
Number · Percentage of Participants
Each Item of UPDRS Part 3 (on State)
Percentage of ParticipantsSPM 962
Speech6.3
Facial Expression5.4
Tremor at Rest (Face, lips, chin)0.6
Tremor at Rest (Left hand)1.6
Tremor at Rest (Right hand)1.6
Tremor at Rest (Left foot)2.2
Tremor at Rest (Right foot)1.6
Action or Postural Tremor of Hands (Left hand)5.4
Action or Postural Tremor of Hands (Right hand)6.6
Rigidity (Neck)5.0
Rigidity (Left upper extremity)2.8
Rigidity (Right upper extremity)2.8
Rigidity (Left lower extremity)5.0
Rigidity (Right lower extremity)4.1
Finger Taps (Left)5.1
Finger Taps (Right)5.7
Hand Movements (Left)7.6
Hand Movements (Right)6.6
Rapid Alternating Movements of Hands (Left)7.3
Rapid Alternating Movements of Hands (Right)6.9
Leg Agility (Left)6.6
Leg Agility (Right)7.3
Arising From Chair9.6
Posture Erect11.4
Gait9.6
Postural Stability8.9
Body Bradykinesia / Hypokinesia7.0
SecondaryEach Item of UPDRS Part 4

The percentage of subjects with elevated scores for each item of UPDRS Part 4. The data at week 52 is shown.

Time frame:
Baseline, up to 54 weeks after dosing.
Reported as:
Number · Percentage of Participants
Each Item of UPDRS Part 4
Percentage of ParticipantsSPM 962
Duration15.1
Disability5.7
Painful Dyskinesias0.6
Presence of Early Morning Dystonia2.5
Are "off" periods predictable?3.2
Are "off" periods unpredictable?1.6
Do "off" periods come on suddenly?1.3
Proportion of "off" in waking day5.7
Patients with anorexia, nausea, or vomiting5.0
Patients with any sleep disturbances10.7
Patient with symptomatic orthostasis1.9

Adverse events

Collected over 54 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPM 962—34/321 (10.6%)290/321 (90.3%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventSPM 962
Gastric Ulcer BleedingGastrointestinal disorders3/321
PneumoniaInfections and infestations2/321
Haematoma SubduralInjury, poisoning and procedural complications2/321
Depressed Level Of ConsciousnessNervous system disorders2/321
Colonic PolypGastrointestinal disorders1/321
HaemorrhoidsGastrointestinal disorders1/321
Hernia InguinalGastrointestinal disorders1/321
Sudden DeathGeneral disorders1/321
CholecystitisHepatobiliary disorders1/321
Herpes ZosterInfections and infestations1/321
Most frequent other events
Showing 10 of 26
Most frequent other events
EventSPM 962
Application Site ReactionGeneral disorders198/321
NasopharyngitisInfections and infestations76/321
DyskinesiaNervous system disorders50/321
Hallucination VisualPsychiatric disorders34/321
NauseaGastrointestinal disorders31/321
Blood Creatine Phosphokinase IncreasedInvestigations26/321
ContusionInjury, poisoning and procedural complications24/321
SomnolencePsychiatric disorders21/321
Dental CariesGastrointestinal disorders20/321
Back PainMusculoskeletal and connective tissue disorders20/321

Baseline characteristics

Age, Continuous
Age, Continuous(years)SPM 962
Mean65.9 ± 8.4
Age, Categorical
Age, Categorical(Participants)SPM 962
<=18 years0
Between 18 and 65 years115
>=65 years206
Sex: Female, Male
Sex: Female, Male(Participants)SPM 962
Female185
Male136
Region of Enrollment
Region of Enrollment(participants)SPM 962
Japan321
08

Study locations

8 sites
  • Chubu Region, Japan
  • Chugoku Region, Japan
  • Hokkaido Region, Japan
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
  • Shikoku Region, Japan
  • Tohoku Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2012
First posted
Jun 29, 2012
Start
Oct 2009
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Mar 19, 2014
Last update
Mar 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01631825
Responsible party
Sponsor
First posted
Jun 29, 2012
Start date
Oct 2009
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Mar 19, 2014
Last update
Mar 19, 2014

Study contacts

Kyoji Imaoka, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion